The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU.
Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a European Healthcare Fund, the first of its kind for BMS, which hails from New York (US).
Many will agree, that BMS is often considered the leader in Immuno-oncology. The range of its resources and clout in the field has granted it first pick for many up and coming blockbusters in Cancer. Indeed, their PD-1 immune checkpoint inhibitor Nivolumab was the first metastatic non-small cell lung cancer (NSCLC) treatment to have been granted EMA approval in over a decade in the EU.
Another investment BMS secured is the ‘Monster Deal’ of €408M with French Innate Pharma, for its phase II combo trial of the monoclonal antibody drug lirilumab which targets Chronic myeloid leukemia (CML).